Skip to main content
. Author manuscript; available in PMC: 2009 Apr 8.
Published in final edited form as: Vaccine. 2008 Feb 20;26(16):2020–2033. doi: 10.1016/j.vaccine.2008.02.009

Table 6.

Effect of CD8+ T cell depletion on vaccine protection after IC challenge with WNV in wild type mice.

Challenge Dose WNV PFU # Survived/Total P value
Placebo vaccine
Isotype control 101 0/10
CD8 mAb depletion 101 0/10
DNA plasmid
Isotype control 101 8/20
CD8 mAb depletion 101 4/20 0.4
Inactivated WNV
Isotype control 101 14/15
CD8 mAb depletion 101 11/15 0.2
Live WNV (survivors)
Isotype control 101 10/10
CD8 mAb depletion 101 10/10 0.7
Placebo vaccine
Isotype control 103 0/10
CD8 mAb depletion 103 0/10
DNA plasmid
Isotype control 103 6/20
CD8 mAb depletion 103 2/20 0.10
Inactivated WNV
Isotype control 103 18/20
CD8 mAb depletion 103 14/20 0.08
Live WNV (survivors)
Isotype control 103 9/10
CD8 mAb depletion 103 9/10 0.6

Mice were vaccinated or infected once as described in Table 1 and on day 58 administered 500 μg of rat anti-mouse CD8 or rat anti-human HLA-DR5 (IgG2b isotype control). Two days later mice were challenged IC with 101 or 103 PFU of WNV and monitored for survival. P values were calculated using the log rank test by comparing the isotype control and CD8 mAb-depleted mice for each vaccine.